Use presentation-specific, dose-specific manufacturer terms—not a single starting-price headline. The following are selected public reference offers retrieved for this review, not wholesale quotations, universal eligibility promises or guaranteed future prices.
| Product and presentation | Published reference pricing | Important condition |
|---|---|---|
| Zepbound single-dose vials or single-patient-use KwikPen | $299 at 2.5 mg; $399 at 5 mg; eligible Journey offer of $449 at 7.5–15 mg | Continuing higher-dose offer requires refill purchase within 45 days of prior delivery/receipt. Regular listed prices are higher at those strengths. A programme month is 28 days. (zepbound.lilly.com) |
| Wegovy injection, 0.25–2.4 mg | Eligible new-patient offer of $199 for each of two introductory fills; standard offer $349 | Introductory offer is limited and subject to year-end terms. (novocare.com) |
| Wegovy HD injection, 7.2 mg | $399 under the published self-pay offer | Do not assume the introductory injection offer applies. (novocare.com) |
| Wegovy tablets | $149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg and 25 mg | One bottle contains 30 tablets; eligibility and programme-change conditions apply. (novocare.com) |
| Foundayo tablets | Starting at $149; temporary offers include $149 at 2.5 mg and $199 at 5.5 mg through December 31, 2026 | Obtain the complete strength-specific schedule and continuing-offer conditions. (foundayo.lilly.com) |
Oral options belong in an updated access catalogue: FDA approved Foundayo in 2026, and the retrieved Wegovy prescribing information includes tablets. This is not a recommendation to switch patients or treat products as interchangeable. (fda.gov)
For year-end orders, inspect the actual operational deadlines. NovoCare’s retrieved terms distinguish prescription-writing, pharmacy-receipt and shipment dates. (novocare.com)
Explore the table row by row
A working view of the research
Zepbound single-dose vials or single-patient-use KwikPen
- Published reference pricing
- $299 at 2.5 mg; $399 at 5 mg; eligible Journey offer of $449 at 7.5–15 mg
- Important condition
- Continuing higher-dose offer requires refill purchase within 45 days of prior delivery/receipt. Regular listed prices are higher at those strengths. A programme month is 28 days. (zepbound.lilly.com)
Sources cited on this page
- zepbound.lilly.com · Source 1 ↗https://zepbound.lilly.com/hcp/coverage-savings
- novocare.com · Source 2 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- foundayo.lilly.com · Source 3 ↗https://foundayo.lilly.com/coverage-savings?utm_source=openai
- fda.gov · Source 4 ↗https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program?utm_source=openai
- novocare.com · Source 5 ↗https://www.novocare.com/eligibility/delivery.html